openPR Logo

Press Releases from SMi Group (888 total)

Lyophilisation 2013 – Freeze-Drying in Pharmaceuticals and Biopharmaceuticals

In pharmaceutical storage and transportation, freeze-drying has been proven an essential method for pharmaceutical companies to distribute and store their products effectively, efficiently and inexpensively. As the industry develops, so do the best methods for this process. SMi is proud to present their inaugural conference on Lyophilisation: Freeze-drying in pharmaceuticals & Biopharmaceuticals, with key talks from Medimmune, GSK Biologicals, National Institute for Biological Standards & Control and Roche on the best

Review developments in combat casualty response | Battlefield Healthcare

Many key developments in healthcare have their origins in the battlefield where the treatment of injured troops has led to innovations throughout history which continue today. The hospital at Camp Bastion in Afghanistan is at the forefront in developments in trauma surgery. Last year it handled 8,000 casualties, many of them with extremely serious injuries. Incredibly, US and British army medics now expect to save 90% of those patients, the highest figure

Last chance to register for UAS 2012

The UK’s leading UAS event will continue to explore the growth and development of the international Unmanned Aerial System market. UAS 2012 will take place in London on the 24th and 25th October 2012. The 2 day event will be playing host to industry experts from across the UAS arena as well as discussing the growth and development of the international Unmanned Aerial System market via case studies from leading experts

Evaluate social media as a valuable strategic resource | Social Media within the …

Social media is a phenomenon. Social networks have made it easy to keep up with friends, organise your life, publicly express thoughts, share interests, provide news snippets and much, much more. It is growing and developing continuously and presents opportunities – and difficulties – to every outward-facing organisation, even the most traditional. The phenomenon of social media has made it easy to keep up with friends, organise your life, publicly

SMi’s 5th Social Media in the Pharmaceutical Industry: Connectivity, Engagemen …

Over the last decade, social media has become integrated into every aspect of business in every industry. The pharmaceutical industry, however, has very traditional methods of research and business development, and in many ways is slow to begin the transition into the online community. SMi Group presents their 5th event in their highly successful series: Social Media in the Pharmaceutical Industry. This conference will allow for key leaders in social media,

SMi’s 4th annual COPD: Novel therapeutics and Management Strategies conference

SMi’s 4th annual COPD: Novel Therapeutics & Management Strategies conference held on the 22nd & 23rd October in London will address therapeutic and management strategies for COPD with an international mix of key opinion leaders in this ever expanding field. It will also provide a comprehensive overview of successful clinical trial design and exacerbation management methods alongside identifying novel targets for COPD therapy, thus paving the way for COPD management

Latest developments in techniques and procedures used in the identification and …

Microbiological contamination of products and processes in a lab and manufacturing environment continues to be a major problem to the Pharmaceutical and Biotechnological industries and its regulators. The potential impact of such contamination can be enormous, and does not only create health and safety problems but can also cost companies millions in lost product revenue. Regulators will endeavour to ensure that the safety of the health care consumer is never

SMi’s 6th annual Biomarkers Summit 2013 - Innovations in stratified medicine

The drive towards personalized medicine is seeing pharma move from patient stratification as a ‘nice to have’, to an essential feature of product development. Exemplified by the success of Herceptin, biomarkers promise to transform drug discovery, clinical development and diagnostics in the R&D process. This dynamic market, poised to reach a value of $33.3 billion by 2015, will continue to improve decision-making, clinical trial success rates

SMi Group Ltd Confirm EDP Distribuição for Smart Grids this September

SMi Group Ltd are pleased to announce Headline Sponsor Vodafone have confirmed for the 2nd annual Telecoms for Smart Grids conference, and their Head of M2M Northern Europe, Kim Bybjerg, will be speaking on Vodafone’s Experiences in Global Smart Metering Implementation. We also are proud to announce that EDP Distribuição have confirmed and will be addressing Distribution Automation and Advanced Meter Infrastructure – Batalha Pilot, led by Francisco Melo, System

Current developments in Neurodegenerative Treatments

The central nervous system is a fundamental part of the human body's response system, creating a massive range of reactions, targets, and in turn, diseases. With increasing average life expectancy, this wide range of disorders (from Alzheimer’s, to Parkinson’s, MS, dementia and depression), is becoming increasingly widespread in the population creating an ever greater need for new treatments and therapies. Clinical trials are still an important area of discussion, with increasing

Partnership factors in sponsor – CRO relationships

Drugs discovered today can realistically cost upwards of 900 million dollars and around 12 years of development to reach a market. CRO’s have been increasingly used by larger pharma to outsource their clinical research, allowing big pharma to shut down in-house R&D, in practice saving money. There have been some issues however with the outsourcing of trials to CROs, including serious relationship break down with negative attitudes, failure to communicate

Harnessing the power of emerging markets

Biosimilar development costs are high with some industry leaders claiming estimates of $100-150 million. Even after this substantial investment there is no guarantee of immediate return. With the FDA, America’s regulatory body, struggling to agree on a suitable approval pathway for biosimilars to reach market in the U.S. and similar marketing and associated costs to innovator drugs, biosimilars have their work cut out. There is an alternative, as biobetters also aim

UK Business Secretary Vince Cable endorses SMi conference key speaker

Vince Cable yesterday endorsed progress in large-scale electricity storage by Isentropic, a key speaker at SMi's upcoming Grid-Scale Energy Storage conference. Using a combined heat pump/heat engine, Isentropic have developed an innovative way to harness a temperature difference to store energy. First, electricity is used to create a large temperature difference (500oC hot and -160oC cold), which can then be stored in two low-cost gravel silos. Recombining the hot

Are exacerbations the most relevant outcome parameters in COPD clinical trials?

COPD is a life threatening disease which negatively affects normal breathing. It is characterised by persistent blockage of air flow to the lungs. COPD encapsulates chronic bronchitis and emphysema. The most common cause of patients getting COPD is tobacco smoke. This is either from smoking or from second hand smoke. COPD is not curable and it is under-diagnosed meaning sufferer numbers may be much larger than are recorded currently. COPD cannot

Next-generation Demand Response software IDROP due to arrive in Europe

‘The electric power industry is going to require powerful analytical engines as we enter the era of Demand Response 2.0...but many of us seem to be forgetting this important requirement,’ declares Smart Grid News. The increasing need for renewable energy has brought about a headache to the energy sector: the sporadic nature of power generation and the consequent challenge of balancing the demand-supply equation. Integral Analytics, a leading supplier

Discuss novel strategies to improve success in cancer vaccines clinical trials i …

There is a great deal of unmet need in the effective treatment of numerous types of cancer, as long-term survival rates are still rather poor for a number of cancers. There is a strong need for more effective therapies that will extend survival, with potential for new immunostimulatory therapies and other biologics to stabilize cancer and prevent metastasis. There have so far only been three cancer vaccines approved by the

Discuss challenges facing new biobanks and building sustainability in London

Single centre research facilities are evolving into research infrastructures as both the number of national biobanks and the efforts to build co-operative networks between them globally increases. Sharing, storing and use of biosamples can vary significantly in cost, social and scientific impact so there are efforts being made to associate value to existing biological resources. The UK government have committed in the region of £250m into research and development, however more

Meet & network with industry experts at Air Mission Planning 2012

With less than 2 weeks until Air Mission Planning 2012, don’t miss this must-attend event for the mission planning community, providing the perfect forum for both commercial and military stakeholders to remain up-to-date with the advances that are improving safety and effect in the skies. Hear distinguished industry experts discuss interoperability, data exchange and cross-domain solutions for the modern mission planner. Delegates will be able to analyse the latest mission planning

Focus on the latest developments in air mission planning

SMi’s 3rd annual Air Mission Planning conference returns to London in less than one month’s time to bring together the foremost experts from: Joint Helicopter Command, USAF, Royal Air Force, South African Forces and NATO Standardisation Agency. Don't miss the chance to hear from an impressive speaker line-up discussing interoperability, data exchange and cross-domain solutions for the modern mission planner. Delegates will be able to analyse the latest mission planning

SMi’s inaugural ADC Summit, 23rd & 24th May 2012, London

Antibody Drug Conjugates are used to fight cancerous cells and are made up of the antibody that will target a specific tumour0-associated antigen a drug often described as payload and the linker. This results in a drug being delivered selectively to the appropriate malignant cell due to the antibody targeting and specific antigen With less than a month away, join SMi at their inaugural ADC Summit conference that will provide a

Understanding how social media benefits the patient and healthcare professionals

The pharmaceutical industry has been waiting for guidance from the FDA and now they have finally shed some light with their 'Off-Label Use' with some mention regarding social media. With this industry moving at a rapid pace, and with more patients and healthcare professionals becoming more tech-savvy, the pharmaceuticals industry need to embrace social media. Building on the tremendous success of SMi's first three Social Media in Pharmaceuticals conference, we are

A Global outlook for the Generics Industry: from commodity to value added Generi …

With only a month to go, SMi is pleased to invite you to attend its Generics, Supergenerics and Patent Strategies conference that will provide you with an excellent overview of the industry and where it stands today along with case studies from the big players in the market. Speakers will showcase how they have handled issues and how they see the industry moving forward. They will also cover some of the

Meet industry experts & discuss the latest advances in drug development at SMi …

Join SMi at the 12th annual Pain Therapeutics conference, which will be held on 21st & 22nd May 2012 in London, UK. Pain is the most common reason patients seek medical care, as it affects the quality of life many people experience and has significant sensory and emotional components. Whilst advances have been made in pain management, few significant ones have occurred, making it harder in recent years to get analgesics

How can smaller companies survive in the European generics industry

SMi's is pleased to announce its Generics, Supergenerics and Patent Strategies conference that will provide you with an excellent overview of the industry and where it stands, along with case studies from the big players in the market showing how they have handled issues and how they see the industry moving forward. We will also be covering some of the current regulatory issues and evaluating big Pharma perspective of their

Strategies for Pharmaceutical Portfolio & Product Life-Cycle Management in face …

There is less than a month away for SMi’s 7th annual Pharmaceutical Portfolio & Lifecycle Management held on the 18th & 19th April in London. The event will address the challenges associated with obtaining an optimal portfolio of projects and senior level industry executives will discuss key strategies and management approaches essential to effective portfolio and lifecycle management. With declining R&D costs, prioritizing a portfolio of successful projects has become essential

Challenges facing new biobanks, strategies for cost recovery and sustainability

Access to samples is paramount to scientific research. Biological samples such as DNA, RNA, proteins, cells and tissues are collected from donors, processed and stored centrally for later use in experiments conducted by academia and industry alike. This has given rise to the concept of Biobanking. In 2009 the market for biobanking products and services was estimated to be worth $8B and is expected to reach $45B by 2025. UK

Examine the latest developments & current issues at SMi’s inaugural ISR confer …

Don't miss SMi's inaugural ISR conference, which will be held in London on 18th & 19th April 2012. This must-attend event will bring delegates and key industry players together, creating networking opportunities and the chance to examine the latest developments and current issues across the air, land, sea, cyber and space communities. ISR 2012 will take a close look at case studies and challenges pertaining to end-users and programme teams across the

Discuss crucial topics & global issues at SMi’s 6th annual MilSpace conference …

SMi's MilSpace 2012 conference is fast approaching, so don’t miss out on this unique opportunity to register for this outstanding event. After 5 successful events, this year will be no exception, bringing together the most senior industry stake-holders and delegates to discuss important topics including interoperability, national space programmes and space situational awareness. MilSpace 2012 will allow attendees the opportunity to network with internationally-recognised Military Space experts from across Europe and

Consider novel linker strategy techniques to increase efficacy of ADC products

Antibody Drug Conjugates are used to fight cancerous cells and are made up of the antibody that will target a specific tumour0-associated antigen a drug often described as payload and the linker. This results in a drug being delivered selectively to the appropriate malignant cell due to the antibody targeting and specific antigen Join SMi at their inaugural ADC Summit held on the 23rd & 24th May 2012 in london that

Extend product lifecycles through reformulation to keep market share

Join SMi at their 9th annual Controlled Release conference to be held on the 28th & 29th March 2012 London. This must-attend event will once again lead the way in examining the latest developments in nanomedicine and featuring fresh presentations from companies including GlaxoSmithKline, Lundbeck, Merck Serono and Genzyme. Controlled Release will allow delegates to meet and network with key decision makers from the top pharmaceutical companies, as well as

Why are the boundaries between innovator and generic companies are becoming blur …

The pharmaceutical generics industry is a fast moving and is a consistently expanding one. With the much referenced patent cliff rapidly approaching, all businesses are looking to generics for a source of additional revenue. SMi's is pleased to announce its Generics, Supergenerics and Patent Strategies conference that will provide you with an excellent overview of the industry and where it stands, along with case studies from the big players in the

6th annual Clinical Trial Logistics Conference

SMi present their 6th annual Clinical Trial Logistics event to be held in London on Tuesday 22nd & Wednesday 23rd of May 2012. This event continues a very successful and high quality series which integrates big Pharma and regulatory speakers to create a complete overview of the Clinical Trial Logistics field. This year’s event will address regulatory change, particularly for handling of temperature sensitive products, duties & taxes, planning a clinical

Network with key industry players at Mobile Deployable Communications 2012, taki …

SMi's Mobile Deployable Communications conference is fast approaching, so don't miss this opportunity to register for this outstanding event. Building on the success of the last five years, this must-attend event once again lead the way in providing the latest overview of in-theatre tactical communications, national roadmaps, technology, NATO and ISAF interoperability and industry support, allowing delegates to meet and network with key decision makers from the military and industry. With

Extend product lifecycles through reformulation to keep market share

Join SMi at their 9th annual Controlled Release conference to be held on the 28th & 29th March 2012 London. This must-attend event will once again lead the way in examining the latest developments in nanomedicine and featuring fresh presentations from companies including GlaxoSmithKline, Lundbeck, Merck Serono and Genzyme. Controlled Release will allow delegates to meet and network with key decision makers from the top pharmaceutical companies, as well as

The latest developments of specific-spectrum, anti-staphyloccal agents using in- …

Now in its 14th year, Superbugs & Superdrugs is a well established antibacterial event that promises to be the perfect forum for networking and problem solving with senior industry executives from the pharmaceutical sector. The event will be held on the 5&6 of March at the Copthorne Tara Hotel, London and will be made up of case-study focused presentations, highlighting success stories and lessons to be learnt. With multidrug resistance ever-increasing

Translational Imaging to improve probability of success in drug development

Join SMi at their 8th annual Imaging in Cancer Drug Development conference that promises to be interactive and informative. With an increasing verity of imaging modalities available and each of them offering benefits at different stages and in different ways, there is a great deal of benefit that can be gained from their implementation. You will hear from industry experts on the current applications of imaging in all stages of drug

Smart water meter market poised for growth | Smart Water Systems, 16-17 April 20 …

“The smart water meter market is poised for steady growth in the coming 5 years, driven by increasing demand for water itself, aging system infrastructure, and a need among utilities to operate their systems much more efficiently”* Maintaining supply and tighter asset management is now essential for water companies. Population growth and environmental pressures are squeezing supply and driving change towards a more sustainable model. Like the energy sector, water

Only 3 weeks left to the leading forum for border security professionals in the …

SMi's inaugural Border Security Asia Pacific conference and exhibition is the only event within the Asia Pacific region to bring together key speakers and professionals from within the border security community. With just 3 weeks to go, don’t miss the opportunity to meet and network with a diverse mixture of international border security experts. Taking part in this event will ensure delegates are kept fully up-to-date with the latest challenges,

Network with leading experts at the JFS&T conference, taking place in 2 weeks

SMi’s 3rd annual Joint Forces Simulation & Training conference, to be held in London on 24th and 25th January 2012, is designed to address the ever-changing operational training needs, technological aspects & challenges within the global training & simulation community. The two-day conference will focus on how the combined multinational forces of land, sea and air work together to prepare for modern combat. Delegates will have the chance to explore the

SMi’s Pharmaceutical Portfolio & Product Lifecycle Management held on 18th & 1 …

Assessing Portfolio value and risk With declining R&D costs, prioritizing a portfolio of successful projects has become essential within the pharmaceutical industry. Lifecycle management approaches must be implemented throughout a products developmental and market period to ensure an increase in profit. Ultimately, the success of pharmaceutical companies relies on crucial project portfolio decisions and understanding of a product’s lifecycle. Don’t miss out on this fantastic opportunity to network with experts in

SMi’s Pharmaceutical Portfolio & Product Lifecycle Management held on 18th & 1 …

With declining R&D costs, prioritizing a portfolio of successful projects has become essential within the pharmaceutical industry. Lifecycle management approaches must be implemented throughout a products developmental and market period to ensure an increase in profit. Ultimately, the success of pharmaceutical companies relies on crucial project portfolio decisions and understanding of a product’s lifecycle. Don’t miss out on this fantastic opportunity to network with experts in the field that includes: Tony

SMi’s 9th annual Controlled Release conference held on the 28th & 29th March 2 …

As formulation and delivery for small molecule and biologics becomes ever more important, targeted delivery and lifecycle extension remain an ongoing need for all concerned. Advances in nanomedicine are meeting these challenges to deliver increasingly sophisticated medicines for oral, parenteral and transdermal extended release therapeutics. Don’t miss out on this fantastic opportunity to network with experts in the field such as: • Peter Timmins, Executive Director, Drug Products, Science and

SMi's Paediatric Clinical Trials conference held on the 21st & 22nd March 2012, …

Many drugs which are prescribed to children have not been adequately studied in the paediatric population. Pharmaceutical companies are now required to produce medicines specifically aimed at 0-17 year olds which has resulted in an increase in paediatric clinical trials. Trials in children are tightly regulated and have both operational and ethical challenges which need to be overcome. Don’t miss out on this fantastic opportunity to network with experts in the

SMi's Orphan Drugs conference held on December 7, 2011

SMi’s Orphan Drugs masterclass aims to tackle the development of orphan drug treatments and the unique challenges involved. The masterclass will help delegates understand what differentiates orphan drugs from other drugs and how to approach the design of development programs for rare diseases. It will be delivered through a combination of diversely skilled speakers who will give presentations, case studies and encourage interaction and discussion. This is designed to help

SMi’s 9th annual Controlled Release conference held on the 28th & 29th March 2 …

Challenges and solutions in the delivery of a prodrug in an oral, extended-release delivery system As formulation and delivery for small molecule and biologics becomes ever more important, targeted delivery and lifecycle extension remain an ongoing need for all concerned. Advances in nanomedicine are meeting these challenges to deliver increasingly sophisticated medicines for oral, parenteral and transdermal extended release therapeutics. Don’t miss out on this fantastic opportunity to network

SMi’s 8th annual Imaging in Cancer Drug Development held on 14th &15th March 2 …

Effective treatments for a wide verity of cancers are still very slow and costly to develop with many prospective drugs ending up in being scraped. With the current economic climate businesses of all sizes are looking for new ways to develop drugs in a smarter manner with reduced production time and improved methods of predicting futility to prevent wasted time and money. Imaging is quickly seen as the way to do

Leading speakers comment on the latest issues in Smartgrid Cyber Security

SmartGrid Cyber Security and Privacy – 14-15th November 2011, Amsterdam There is just over a month until SMi’s SmartGrid Privacy conference, and with smart meters being rolled out throughout Europe daily it represents a great opportunity to bring about a paradigm shift in the way in which consumers use electricity and understand their consumption habits. However the way in which smart meters' systems are designed and deployed present numerous challenges and

The current status on security and privacy files in the Netherlands and in Bruss …

The vision of the future Smart Grid involves an unprecedented transformation of our current electrical industry, with the introduction and integration of intelligent communications architecture. While the benefits of carbon reduction, reliability and controlled consumption remain firm drivers to support this change, the vulnerability and threat profile associated with the business model remain a critical priority. SMi’s Smart Grid Cyber Security and Privacy Forum will address the threat landscape of cyber attacks,

Leading UK and UAV based forum discusses challenges in the unmanned aerial domai …

--------------------------------------------------- FOR IMMEDIATE RELEASE ---------------------------------------------- SMi Group is delighted to announce their 11th annual Unmanned Aircraft Systems conference, to be held on the 16th & 17th October 2011 in London. The leading UK and UAV based conference provides a forum for global thought leadership and knowledge sharing, and concisely meets the challenges presented by the annual growth that occurs in what is the most dynamic community within the aviation sector. UAS 2011

Securing the Smart Grid cyber infrastructure

Securing the Smart Grid cyber infrastructure The vision of the future Smart Grid involves an unprecedented transformation of our current electrical industry, with the introduction and integration of intelligent communications architecture. While the benefits of carbon reduction, reliability and controlled consumption remain firm drivers to support this change, the vulnerability and threat profile associated with the business model remain a critical priority. SMi’s Smart Grid Cyber Security and Privacy Forum will address

Go To Page:    11 12 13 14 15 16 17 18 19 20